The fluticasone/salmeterol combination product is superior to montelukast as first-line asthma control

P. Dorinsky, C. Kalberg, P. Pepsin, A. Emmett, B. Bowers, K. Rickard (Research Triangle Park, United States Of America)

Source: Annual Congress 2001 - Leukotriene receptor antagonists in clinical practice
Session: Leukotriene receptor antagonists in clinical practice
Session type: Thematic Poster Session
Number: 1780
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Dorinsky, C. Kalberg, P. Pepsin, A. Emmett, B. Bowers, K. Rickard (Research Triangle Park, United States Of America). The fluticasone/salmeterol combination product is superior to montelukast as first-line asthma control. Eur Respir J 2001; 16: Suppl. 31, 1780

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

The cost-effectiveness of achieving asthma control with the combination products salmeterol/fluticasone propionate or formoterol/budesonide
Source: Eur Respir J 2001; 18: Suppl. 33, 159s
Year: 2001

Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020




Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma
Source: Eur Respir J 2007; 29: 682-689
Year: 2007



Triple combination of montelukast or tiotropium and inhaled corticosteroids plus long-acting ß2-agonist in persistent asthma
Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases
Year: 2018




Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Low-dose fluticasone is superior to montelukast in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 509s
Year: 2004

Efficacy of montelukast as complementary therapy to fixed association ICS/LABA in asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 126s
Year: 2004

Low-dose single-inhaler budesonide/formoterol administered once daily is effective in mild-persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 158s
Year: 2001

Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
Source: ERJ Open Res 2016: 00106-2015
Year: 2016



Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Combination therapy with maintenance budesonide and formoterol in COPD
Source: Eur Respir J 2004; 24: 1070
Year: 2004


Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics
Source: International Congress 2017 – Clinical points to ponder in asthma
Year: 2017


Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Comparison of beclomethasone/formoterol and fluticasone/salmeterol fixed combinations for weekly asthma control
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2agonists (LABA) + inhaled corticosteroids (ICS)
Source: Eur Respir J 2003; 22: Suppl. 45, 312s
Year: 2003

Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002